The Annual International Meeting of the Institute of Human Virology (IHV) had its start in the mid-1970s when a small gathering of collaborators began to assemble under the leadership of Dr. Robert C. Gallo, then Chief of the Laboratory of Tumor Cell Biology at the National Cancer Institute in Bethesda, MD. Long before the 1996 establishment of IHV, the meeting was expanded to include discussions around tumor cell biology, retrovirology, and HIV/AIDS, among others. The meeting achieved rapid growth and even greater interest after the 1980 discovery of the first human retrovirus, HTLV-I, by Gallo and his colleagues.
When the University of Maryland recruited Gallo, Bill Blattner (National Cancer Institute) and Bob Redfield (Walter Reed Army Hospital) to create a bench-to-bedside Institute, the meeting followed and is now associated with the University of Maryland School of Medicine.
The Annual Meeting will feature themes on HIV cure research; HIV pathogenesis; HIV structural biology, immunology and vaccines; advances in clinical, prevention and public health research, and a cross-cutting session on the molecular and immunological insights from cancer biology and treatment.
The Institute of Human Virology (IHV) is the first center in the United States - perhaps the world - to combine the disciplines of basic science, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably HIV, the cause of AIDS.
Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in the field of human virology. IHV was co-founded by Robert Gallo, MD, director of the of the IHV, William Blattner, MD, associate director of the IHV and director of IHV’s Division of Epidemiology and Prevention and Robert Redfield, MD, associate director of the IHV and director of IHV’s Division of Clinical Care and Research. IHV is also comprised of an Animal Models Division, Basic Science Division and Vaccine Research Division.